Clinical Trials
15 trialsNCT03260894 2026-05-22
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Incyte Corporation
Phase 3 Completed
NCT01575548 2026-05-04
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT06726421 2026-01-15
STROKER
Sun Yat-sen University
Phase 3 Recruiting
NCT06263231 2025-07-29
INVINCIBLE-3
Intensity Therapeutics, Inc.
Phase 3 Active not recruiting
NCT03592472 2025-04-13
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
Xynomic Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT00720941 2025-03-30
COMPARZ
Novartis
Phase 3 Completed
NCT02049905 2024-06-13
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
ImmunityBio, Inc.
Phase 3 Completed
NCT04741438 2023-08-30
RAR-Immune
Centre Leon Berard
Phase 3 Unknown
NCT00866697 2021-02-16
Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Novartis
Phase 3 Completed
NCT01235962 2020-11-23
PROTECT
Novartis
Phase 3 Completed
NCT02979899 2020-05-12
TAPPAS
Tracon Pharmaceuticals Inc.
Phase 3 Completed
NCT01064310 2017-04-17
PISCES
Novartis
Phase 3 Completed
NCT00334282 2016-02-05
Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma
GlaxoSmithKline
Phase 3 Completed
NCT00387764 2014-01-14
Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer
GlaxoSmithKline
Phase 3 Completed
NCT00753688 2013-08-22
PALETTE
GlaxoSmithKline
Phase 3 Completed